Cash-strapped gene-therapy company Bluebird bio agreed to be acquired by private-equity firms Carlyle Group and SK Capital Partners in a deal potentially worth up to $96 million.

Just a few weeks ago, Merck (known as MSD outside North America) paid $425 million to get hold of OncoImmune. The headline of the deal was an experimental COVID-19 drug, but it also claimed rights ...

Bin Liu, PhD, associate professor at The Hormel Institute, University of Minnesota, is among the authors of a newly published paper appearing in the leading scientific journal Nature, entitled ...